Bildkälla: Stockfoto

InDex Pharmaceuticals Q4’21: Our Comments - Redeye

Redeye leaves its comment on InDex following the announcement of its year-end report. CONCLUDE seems to be developing according to plan; we maintain our positive view on InDex shares.

Redeye leaves its comment on InDex following the announcement of its year-end report. CONCLUDE seems to be developing according to plan; we maintain our positive view on InDex shares.
Börsvärldens nyhetsbrev
ANNONSER